AUA2025: Chemotherapy and Immunotherapy for Urologists and Advanced Practice Providers (APPs)
Update: 2025-07-30
Description
AUA2025: Chemotherapy and Immunotherapy for Urologists and Advanced Practice Providers (APPs)
CME Available: https://auau.auanet.org/node/43009
At the conclusion of this activity, participants will be able to:
1. Identify the guidelines for first-line and beyond treatment of patients with hormone-sensitive advanced and metastatic prostate cancer, including medications, their mechanism, side effects and efficacy.
2. Summarize the recommendations for first-line and beyond treatment of castrate-resistant metastatic and nonmetastatic prostate cancer, including medications, their mechanism, side effects and efficacy.
3. Diagram the treatment options for high-risk non-muscle invasive bladder cancer.
4. Distinguish the guideline-defined therapeutic options for locally advanced and metastatic bladder cancer.
5. Discuss treatment options for locally advanced and metastatic kidney cancer, including medications, their mechanism, side effects and efficacy.
ACKNOWLEDGEMENTS:
This educational activity is supported by independent educational grants from:
Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
CME Available: https://auau.auanet.org/node/43009
At the conclusion of this activity, participants will be able to:
1. Identify the guidelines for first-line and beyond treatment of patients with hormone-sensitive advanced and metastatic prostate cancer, including medications, their mechanism, side effects and efficacy.
2. Summarize the recommendations for first-line and beyond treatment of castrate-resistant metastatic and nonmetastatic prostate cancer, including medications, their mechanism, side effects and efficacy.
3. Diagram the treatment options for high-risk non-muscle invasive bladder cancer.
4. Distinguish the guideline-defined therapeutic options for locally advanced and metastatic bladder cancer.
5. Discuss treatment options for locally advanced and metastatic kidney cancer, including medications, their mechanism, side effects and efficacy.
ACKNOWLEDGEMENTS:
This educational activity is supported by independent educational grants from:
Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
